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Aims Atrial fibrillation (AF) and thrombo-embolism (TE) are associated with reduced survival in hypertrophic cardiomy-
opathy (HCM), but the absolute risk of TE in patients with and without AF is unclear. The primary aim of this study
was to derive and validate a model for estimating the risk of TE in HCM. Exploratory analyses were performed to
determine predictors of TE, the performance of the CHA2DS2-VASc score, and outcome with vitamin K antagonists
(VKAs).
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Methods
and results
A retrospective, longitudinal cohort of seven institutions was used to develop multivariable Cox regression models
fitted with pre-selected predictors. Bootstrapping was used for validation. Of 4821 HCM patients recruited between
1986 and 2008, 172 (3.6%) reached the primary endpoint of cerebrovascular accident (CVA), transient ischaemic
attack (TIA), or systemic peripheral embolus within 10 years. A total of 27.5% of patients had a CHA2DS2-VASc
score of 0, of whom 9.8% developed TE during follow-up. Cox regression revealed an association between TE and
age, AF, the interaction between age and AF, TE prior to first evaluation, NYHA class, left atrial (LA) diameter,
vascular disease, and maximal LV wall thickness. There was a curvilinear relationship between LA size and TE risk.
The model predicted TE with a C-index of 0.75 [95% confidence interval (CI) 0.70–0.80] and the D-statistic was
1.30 (95% CI 1.05–1.56). VKA treatment was associated with a 54.8% (95% CI 31–97%, P = 0.037) relative risk
reduction in HCM patients with AF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusions The study shows that the risk of TE in HCM patients can be identified using a small number of simple clinical features.
LA size, in particular, should be monitored closely, and the assessment and treatment of conventional vascular risk
factors should be routine practice in older patients. Exploratory analyses show for the first time evidence for a
reduction of TE with VKA treatment. The CHA2DS2-VASc score does not appear to correlate well with the clinical
outcome in patients with HCM and should not be used to assess TE risk in this population.
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Introduction
Hypertrophic cardiomyopathy (HCM) is a myocardial disorder
characterized by LV hypertrophy not explained solely by abnormal
loading conditions. It is inherited as an autosomal dominant trait
and caused by mutations in cardiac sarcomere protein genes.1–3
Atrial fibrillation (AF) and thrombo-embolism (TE) are common
complications of the disease and are associated with adverse clinical
outcomes and reduced survival.4–9 However, HCM is a hetero-
geneous disorder with very variable clinical presentation, and the
absolute risk of TE—and by implication the likely benefit from
treatment—in individual patients with different clinical character-
istics is unknown.1,10–12
The primary aim of this study was to derive and validate a
risk model for estimating the risk of TE in patients with HCM.
Exploratory analyses were performed to determine clinical predic-
tors of TE, the performance of the CHA2DS2-VASc score,
13 and
the outcome of therapy with vitamin K antagonists (VKAs) in HCM
patients with AF.
Methods
Study design and overview
Data from a retrospective, multicentre longitudinal cohort—the
Hypertrophic Cardiomyopathy Outcome Investigators
(www.HCMRisk.org)14—were used in the development of the
prognostic model.
The study conforms to the principles of the Helsinki declaration.
The sponsors of this study did not have a role in study design,
data collection, analysis, and interpretation. O.G., M.P., R.O., and
P.E. had access to all data and final responsibility to submit the
article. The authors from each centre guarantee the integrity of data
from their institution. All investigators have agreed to the article as
written.
Study population and participating
centres
The study cohort consisted of all consecutively evaluated patients with
HCM, followed at seven European centres: (i) The Heart Hospital,
London, UK; (ii) A Coruna University Hospital, A Coruna, Spain;
(iii) Unit of Inherited Cardiovascular diseases, 1st Department of
Cardiology, University of Athens, Greece; (iv) Institute of Cardiology,
University of Bologna, Italy; (v) University Hospital Virgen de la
Arrixaca, Murcia, Spain; (vi) Monaldi Hospital, Second University of
Naples, Italy; and (vii) Hospital Universitario Puerta del Hierro, Madrid,
Spain. Some patients from this cohort are reported in other recently
published studies.14–25
Only adult patients (≥16 years of age) were studied. HCM was
defined as a maximum LV wall thickness ≥15mm unexplained solely
by loading conditions1 or in accordance with published criteria for the
diagnosis of disease in relatives of patients with unequivocal disease.26
Patients with known inherited metabolic diseases or syndromic causes
of HCM were excluded from the study. Patients with a history of AF
that had experienced TE prior to first evaluation at the centre were
also excluded from the analysis. ..
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.. Ethics approval
Patients at A Coruna University Hospital (Spain), 1st Department
of Cardiology, University of Athens (Greece), University Hospital
Virgen de la Arrixaca (Spain), and Monaldi Hospital (Italy) provided
written informed consent. The data collection at The Heart Hospital
(UK) and Hospital Universitario Puerta de Hierro (Spain) have been
approved by the appropriate ethics committee. The ethics committee
at the Institute of Cardiology at the University of Bologna (Italy)
were informed, but approval was not required under local research
governance arrangements.
Patient assessment and data collection
Patients were reviewed every 6–12 months or earlier if there was a
change in symptoms. All patients underwent clinical assessment, pedi-
gree analysis, physical examination, resting and ambulatory ECG, and
transthoracic echocardiography. Each centre collected data indepen-
dently using the same methodology.
Clinical outcomes
The primary outcome was a thrombo-embolic event defined as a
composite of cerebrovascular accident (CVA), transient ischaemic
attack (TIA), or systemic peripheral embolus as defined in the
CHA2DS2-VASc score.
10,12 A CVA was defined as a focal neurologi-
cal deficit of sudden onset as diagnosed by a neurologist, lasting >24 h
and caused by ischaemia. A TIA was defined as a focal neurological
deficit of sudden onset as diagnosed by a neurologist, lasting <24 h.
Peripheral embolism was defined as TE outside the brain, heart, eyes,
and lungs.13
Selection of predictors and coding
Following a review of the literature completed in September 2012,
predictors of TE that have been reported previously in patients with
HCM were considered as candidate predictor variables.27 Clinical
parameters were used as pre-specified predictors only when associated
with TE in at least one published study, and were uniformly defined in all
centres. In addition, predictors included in the CHA2DS2-VASc score,
and maximal LV wall thickness and peak left ventricular outflow tract
(LVOT) gradient were considered for the analysis (Table 1). Clinically
plausible interactions between selected variables such as age and AF
and age and vascular disease were also assessed. All predictors were
assessed at baseline evaluation.
Sample size
A minimum of 10 thrombo-embolic events were required per coeffi-
cient estimated by the model to ensure that the regression coefficients
of the model were estimated with adequate precision.28 The 172 TE
endpoints observed in this cohort over a 10-year follow-up period
allow the estimation of up to 17 regression coefficients with adequate
precision and were sufficient for development of the risk model.
General statistical methods
STATA (version 12) and R (version 3.0) were used for the statisti-
cal analyses. For descriptive results, variables are expressed as the
mean± standard deviation (SD), median and interquartile range (IQR),
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Definition of pre-specified predictor variables assessed at baseline evaluation
Predictor variable Definition Coding
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sex Male or female44 Binary, male/female
Age Age at first evaluation in participating centres43,45 Continuous, years
VKA Use of vitamin K antagonist at first evaluation Binary, yes/no
AF Detection of paroxysmal, permanent of persistent AF on ECG or Holter monitoring43,45 Binary, yes/no
TE Thrombo-embolism: CVA, TIA, peripheral embolus, as per CHA2DS2-VASc score
10,12 Binary, yes/no
NYHA NYHA class at first evaluation45 Categorical, I, II and III–IV
LA Anterior–posterior left atrial diameter determined by 2D echocardiography in the
parasternal long axis–short axis plane at time of first evaluation44
Continuous, mm
MWT The greatest LV wall thickness measured at the level of the mitral valve, papillary muscles, and
apex in the parasternal short axis plane using 2D echocardiography at time of evaluation46
Continuous, mm
FS LV end-diastolic dimension – LV end-systolic dimension)/LV end-diastolic dimension
measured by M-Mode or 2D echocardiography at time of evaluation44
Continuous, %
LVOT max The maximum LV outflow gradient determined at rest and with Valsalva provocation
(irrespective of concurrent medical treatment) using pulsed and continuous wave Doppler
from the apical three- and five-chamber views Peak outflow tract gradients were
determined using the modified Bernoulli equation: gradient= 4V2, where V is the peak
aortic outflow velocity47
Continuous, mmHg
Hypertension Diagnosis of hypertension prior to first evaluation, as per CHA2DS2-VASc score
10,12 Binary, yes/no
Diabetes Diagnosis of diabetes prior to first evaluation, as per CHA2DS2-VASc score
10,12 Binary, yes/no
Vascular disease Myocardial infarction, complex aortic plaque, and peripheral arterial disease, as per
CHA2DS2-VASc score
10,12
Binary, yes/no
Heart failure Heart failure, especially moderate to severe LV systolic dysfunction, defined arbitrarily as
LVEF <40% (calculated by FS), as per CHA2DS2-VASc score
10,12
Binary, yes/no
FS, fractional shortening; LA, left atrial size, LVOT max, maximum LV outflow gradient; MWT, aximal wall thickness; TE, thrombo-embolic event; VKA, vitamin K antagonist.
or counts and percentages as appropriate. The follow-up time for each
patient was calculated from the date of their first evaluation at partic-
ipating centres to the date of the study endpoint, death, heart trans-
plantation, cerebral haemorrhage, or the date of their most recent
evaluation. The annual event rate was calculated by dividing the num-
ber of patients reaching the endpoint by the total follow-up period for
that endpoint. The Kaplan–Meier method was used to estimate the
cumulative probability for the occurrence of an outcome.
Missing data
The characteristics of patients with missing information were com-
pared with those of patients with complete information to investigate
bias due to missing data. Logistic regression was used to identify the
predictors of missingness. Data were assumed to be missing at ran-
dom, and values for the missing predictors were imputed using multi-
ple imputation techniques based on chained equations.29 The multiple
imputation model included all predictors of missingness, the outcome,
all pre-specified predictors of the risk model, and the estimate of the
cumulative hazard function.30 Rubin’s rules were used to combine the
estimates from 30 imputed data sets.31
Model development
All pre-specified predictors were candidates for inclusion in the final
risk model. To account for potential non-linear relationships, we con-
sidered the addition of quadratic terms for all continuous predictors.
Due to sample size issues, this was done in a pre-selection procedure
where bi-variable models for each predictor and its quadratic term .
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. were fitted. Suspected interactions were also examined in a similar
manner.
The model was developed based on the 172 events within the first
10 years of follow-up. Backward elimination with a 15% significance
level was used to select the predictors for the final risk model.32 Centre
was not included to allow the model to be used in patients from other
centres. However, a sensitivity analysis for centre effect was performed
by including centre in the model. The proportional hazards assump-
tion required by the Cox model was investigated using Schoenfeld
residuals.33 The risk model was developed using the entire cohort.
Model validation
Bootstrapping was used to evaluate the performance of the model. This
is the most efficient internal validation procedure as all aspects of the
model development, including variable selection, are validated.34 Two
hundred bootstrap samples were generated for each imputed data set,
and the optimism-adjusted performance measures from the imputed
data sets were combined using Rubin’s rules.35 The calibration slope
was used to assess the degree of agreement between the observed
and predicted hazards of TE.36 A value close to 1 suggests good overall
agreement. Graphical comparisons of the observed and predicted TE
at 5 years were performed. The C-index and D-statistic were used to
measure how well the model discriminated between patients with high
and low risk of TE.14,37–39 A value of 0.5 for the C-index indicates no
discrimination, and a value equal to 1 indicates perfect discrimination.
The D-statistic can be interpreted as the log hazard ratio (HR) for
having TE between the low and high risk groups of patients. A model
with no discriminatory ability results in a value of 0 for the D-statistic,
with increasing values indicating greater separation.
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Clinical characteristics at baseline of the whole cohort and in patients with and without a thrombo-embolic
endpoint
Predictor Whole cohort No TE TE
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total Mean (SD)/n (%) Total Mean (SD)/n (%) Total Mean (SD)/n (%)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age 4817 48.99 (16.40) 4645 48.74 (16.39) 172 55.73 (15.40)
LA 4627 43.97 (7.74) 4460 43.82 (7.68) 167 47.83 (8.37)
MWT 4768 19.44 (5.15) 4599 19.42 (5.18) 169 20.05 (4.16)
FS 4358 0.41 (0.10) 4198 0.41 (0.10) 160 0.40 (0.09)
LVOT max 4168 31.95 (40.94) 4023 31.85 (40.96) 145 34.72 (40.46)
Female 4820 1740 (36.10) 4648 1666 (35.84) 172 74 (43.02)
Prior TE 4821 80 (1.66) 4649 71 (1.53) 172 9 (5.23)
AF 4815 600 (12.46) 4643 552 (11.89) 172 48 (27.91)
VKA 4818 443 (9.20) 4646 410 (8.82) 172 33 (19.19)
NYHA II 4615 1584 (34.32) 4450 1519 (34.13) 165 65 (39.29)
NYHA III, IV 4615 494 (10.70) 4450 456 (10.24) 165 38 (23.03)
Vascular disease 3588 89 (2.48) 3438 79 (22.98) 150 10 (6.67)
Hypertension 4712 1414 (30.00) 4541 1354 (29.82) 171 60 (35.09)
Diabetes 4020 293 (7.29) 3868 279 (7.21) 152 14 (9.21)
Breakdown of AF in the whole cohort: paroxysmal 314, persistent 102, permanent 181, not specified 3.
FS, fractional shortening; LA, left atrial size, LVOT max, maximum LV outflow gradient; MWT, aximal wall thickness; SD, standard deviation; TE, thrombo-embolic event; VKA,
vitamin K antagonist.
Model presentation
The probability of TE at 5 years for an individual patient was calculated
using the following equation, derived from the Cox proportional
hazards model:
PTE at 5 years = 1–S0 (t)exp (prognostic index)
where S0(t) is the average survival probability at time t (i.e. at 5 years),
and the prognostic index is the sum of the products of the predictors
and their coefficients.
Calculation of the CHA2DS2-VASc score
The CHA2DS2-VASc score was calculated for a subset of patients with
AF not treated with a VKA at baseline.10,12,13 The distribution of the
score and number of events according to the score was determined.
Clinical outcome of anticoagulation
in patients with atrial fibrillation
The incidence of TE in patients with AF who were and were not
treated with anticoagulants was investigated using an intention to treat
analysis. If a patient received treatment with a VKA at any time prior
to the event, it was assumed that they continued on this medication
for the duration of the study. The numbers of patients with and
without TE that did or did not receive a VKA were compared. The
absolute risk reduction (ARR) and number needed to treat (NNT)
were calculated for patients in AF at an exploratory threshold of 4%
risk of a thrombo-embolic event over 5 years.
Relationship of patient characteristics
to thrombo-embolic risk
Pre-specified subanalyses were performed to assess the relationship
between the 5-year risk of TE and age, vascular disease, and left atrial .
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.. (LA) size. Secondary analyses were performed in patients in sinus
rhythm (SR) who experienced TE and patients with AF who did not
experience TE.
Results
Baseline clinical characteristics
During the study period, 5104 patients were evaluated, of whom
197 were seen only once for baseline evaluation and were excluded
from the analysis. Eighty-six patients with a history of AF and TE
prior to first evaluation were excluded. The final study cohort
consisted of the remaining 4821 patients, and the baseline clinical
characteristics are shown in Table 2.
Thrombo-embolic events during
follow-up
During a follow-up period of 28 330.6 patient-years (median
6.0 years, IQR= 3–9.7), 172 (3.6%) patients reached the primary
endpoint within 10 years from first evaluation (105 CVA, 53
TIA, and 14 peripheral emboli); and 107 (2.2%) patients within
the first 5 years. The 5- and 10-year cumulative incidences were
2.9% [95% confidence interval (CI) 2.37–3.48%) and 6.4% (95% CI
5.42–7.53%), respectively. The clinical characteristics of patients
with and without TE are shown in Table 2.
Patients in SR at first evaluation who developed TE dur-
ing follow-up were older (55.0 years vs. 47.5 years; difference in
means= 7.5 years; 95% CI 4.60–10.42), had larger LA diame-
ter (46.0mm vs. 43.0mm; difference in means= 3.0mm; 95% CI
1.7–4.32), and were more symptomatic (NYHA III, IV) (14.4% vs.
9.0%; difference in proportions= 0.054; 95% CI 0.0099–0.1181)
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Exploratory univariable and multivariable analysis for predictors of thrombo-embolism in hypertrophic
cardiomyopathy
Univariable analysis Multivariable analysis
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Predictor HR P-value 95% CI Predictor HR P-value 95% CI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sex 1.43 0.02 1.06–1.93 AGE 1.03 <0.001 1.02–1.04
AGE10 1.45 <0.001 1.31–1.60 AF 8.41 <0.001 1.95–36.35
AF 3 <0.001 2.15–4.19 age_af 0.97 0.03 0.95–1.00
Prior TE 4.15 <0.001 2.12–8.13 Prior TE 3.63 <0.001 1.81–7.29
NYHA II 1.61 0.01 1.14–2.29 NYHA II 1.25 0.21 0.88–1.78
NYHA III, IV 3.66 <0.001 2.44–5.48 NYHA III, IV 2.07 <0.001 1.35–3.17
LA5 1.36 <0.001 1.24–1.48 LA 1.03 <0.001 1.01–1.05
MWT 1.01 0.3 0.99–1.04 MWT 1.45 <0.001 1.12–1.88
FS 0.22 0.08 0.04–1.20 MWT2 0.99 0.01 0.99–1.00
EF 0.3 0.08 0.08–1.16 Vascular disease 1.67 0.12 0.88–3.18
LVEDD 1 0.88 0.98–1.03
LVESD 1.01 0.29 0.99–1.04
LVOT max 1 0.09 1.00–1.01
Hypertension 1.46 0.02 1.06–1.99
Diabetes 1.36 0.27 0.79–2.36
Vascular disease 3.2 <0.001 1.68–6.07
MWT 1.67 <0.001 1.29–2.16
MWT2 0.99 <0.001 0.98–0.99
AGE10, hazard ratio for 10-year increments; age_af, interaction between age and AF; CI, confidence interval; FS, fractional shortening; HR, hazard ratio; LA5, hazard ratio for
left atrial size for 5mm increments; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LVOT max: maximum LV outflow gradient;
MWT, maximal wall thickness; TE, thrombo-embolic; VKA, vitamin K antagonist.
MWT and MWT2 in the last two rows of the table adjust for MWT and its square term.
compared with patients who did not have an event. There was
also a higher percentage of patients with vascular disease (5.7% vs.
2.0%; difference in proportions= 0.037; 95% CI 0.0074–0.0812) in
the event cohort (Supplementary material online, Table S1). The
mean age of patients with and without vascular disease was 62.4
and 49.1 years, respectively.
Missing data
Missing data per variable are described in the Supplementary
material online, Table S2.
Model development
Univariable analyses are shown in Table 3. Only maximal LV wall
thickness was found to have a non-linear association with TE,
and so a quadratic term was included as a candidate for the final
prognostic model. The interaction between AF and age was also
found to be significant. There were 15 predictors (16 regression
coefficients) which were candidates for the final model.
Age, AF, the interaction between age and AF, TE prior to first
evaluation, NYHA class II, NYHA class III and IV, LA diameter,
vascular disease, maximal LV wall thickness, and (maximal LV wall
thickness)2 were included in the risk model. The estimates of the
HRs and the corresponding CIs for the risk prediction model are
shown in Table 3. There was no significant centre effect as part
of a sensitivity analysis (shown in Supplementary material online,
Table S3). .
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. The risk of TE in 5 years for an individual HCM patient can be
calculated from the following equation:
PTE at 5 years = 1– 0.9999874
exp (prognostic index)
where the prognostic index= 0.030417476× age (years)+
2.129977874× af (yes=1/no= 0) – 0.027069595× age× af+
1.288557829×TE prior (yes= 1/no= 0)+ 0.224673046× nyha
class II (yes=1/no= 0)+ 0.728180341× nyha class III/IV (yes=1/
no= 0)+ 0.032251831× la diam (mm)+ 0.3735254×mwt (mm)
–0.008324216×mwt2 (mm)+ 0.512492795× vascular disease
(yes= 1/no= 0).
Model validation
Bootstrapping showed a good calibration slope of 0.91 (95%
CI 0.74–1.08). Figure S1 in the Supplementary material online
illustrates a good agreement between the observed and predicted
risk at exploratory thresholds of thrombo-embolic risk at 5 years.
The C-index was 0.75 (95% CI 0.70–0.80) and the D-statistic was
1.30 (95% CI 1.05–1.56), indicating good discrimination.
Comparison with conventional stroke
prediction models
A total of 222 patients with complete data and AF were not treated
with a VKA at baseline evaluation; of these, 61 (27.5%) had a
CHA2DS2-VASc score of 0 and 19 (8.6%) had a score between 4
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Kaplan–Meier failure estimates for cumulative incidence of thrombo-embolism (TE). (A) The cumulative incidence of TE according
to CHA2DS2-VASc score groups (low= 0, 61 patients; intermediate= 1, 72 patients; high> 2, 89 patients). (B) The cumulative incidence of TE
according to the 5-year risk prediction model (low= 0–1.5%, 1643 patients; medium–low=1.5–3%, 887 patients; medium–high= 3–5%, 494
patients; high >5%, 287 patients).
and 6. No patient had a score of 7–9. Table S4 of the Supplementary
material online presents the prevalence of TE in patients according
to CHA2DS2-VASc score.
Figure 1 displays the cumulative incidence of TE according to
CHA2DS2-VASc score groups and according to the 5-year risk
prediction model.
Relationship between anticoagulation
and thrombo-embolism risk in patients
with atrial fibrillation
Table S5 of the Supplementary material online presents an unad-
justed exploratory analysis of the prevalence of TE over 10 years in
patients with AF at first evaluation that did or did not receive a VKA
during the follow-up period prior to TE; 12.4% of those not receiv-
ing a VKA and 6.8% of patients of those who were receiving anti-
coagulation had a thrombo-embolic event. This corresponds to a
relative risk reduction of 54.8% (95% CI 0.31–0.97, P= 0.037) with
VKA treatment. Figure 2 displays the Kaplan–Meier curves compar-
ing VKA and non-VKA groups. The ARR and NNT for patients in
AF at an exploratory threshold of 4% risk of a thrombo-embolic
event over 5 years is 13% (95% CI 2.1–24%) and 7.7, respec-
tively. These results should be interpreted with caution as the small
numbers meant that a standard multivariable model adjusting for
warfarin and the rest of the predictors was not appropriate. Instead
we fitted a multivariable model as a sensitivity analysis using Lasso
regression, a penalized regression method suitable for data sets
with few events.40 In this fully adjusted analysis, warfarin maintained
its protective effect (results not shown).
We also used propensity score analysis to explore further
the indication for the effect of VKA on stroke. The propensity
score for each patient was calculated as the predicted probability
of receiving a VKA. It is clinical practice in the participating
centres to consider therapy with VKA in patients with significantly .
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Figure 2 Kaplan–Meier failure estimates comparing thromb-
oembolic events (TE) in vitamin K antagonist (VKA) and non-VKA
groups.
enlarged LA diameter. Indeed LA was the strongest balancing factor
in the propensity score model to identify treatment allocation
variables, while older age, history of diabetes, and smaller fractional
shortening were also associated with higher probability of receiving
a VKA. Subsequently a Cox regression model for the time to TE
adjusting for VKA and the propensity score41 showed that VKA
maintained its protective effect (HR 0.41; 95% CI 0.22–0.76).
Relationship of left atrial size to risk
of thrombo-embolic events
Figure 3 shows the relationship between LA size and 5-year risk of
TE. There appears to be a linear relationship up to ∼45–50mm, at
which point the risk of TE rises exponentially with increasing LA
diameter. In the cohort of patients in SR at first evaluation with
an LA diameter >50mm, the prevalence of a thrombo-embolic
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Relationship of left atrial (LA) size to risk of
thrombo-embolism (TE).
event was 4.7% (Supplementary material online, Table S6). Patients
with an event in this group were older (55.8 years vs. 50.1 years) as
compared with patients who did not experience an event. Patients
in AF who did not develop a thrombo-embolic event had a smaller
LA diameter (50.0mm vs. 52.3mm) and were less symptomatic
(NYHA III, IV) (19.6% vs. 44.7%) compared with patients with
an event. The characteristics are displayed in the Supplementary
material online, Table S1.
Discussion
In this study we present the first validated model for TE prediction
in a diverse population of adult patients with HCM. The study
confirms the high risk of TE in patients with AF and the strong
association between atrial size and thrombo-embolic risk.7,8,27
It also demonstrates an association with several other patient
characteristics including age, heart failure symptoms, and maximal
LV wall thickness and, for the first time in this population, vascular
disease.
CHA2DS2-VASc score in hypertrophic
cardiomyopathy
Clinical guidelines recommend the CHA2DS2-VASc score as a
means of stratifying patients with non-valvular AF for antithrom-
botic prophylaxis.10,12,13 We show that this score has a relatively
low predictive accuracy in patients with HCM that is proba-
bly explained by the lower prevalence of vascular risk factors.
These data support recent consensus guidelines from the Euro-
pean Society of Cardiology (ESC) that advise against the use of the
CHA2DS2-VASc score in patients with HCM.
1
Clinical outcome of anticoagulation
in patients with atrial fibrillation
There are no prospective randomized trials of any therapy for
AF in HCM including anticoagulation, and only a very small num-
ber of observational studies comparing VKAs with antiplatelet ..
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.. drugs.7,8,42,43 In this study, an intention to treat analysis of VKA
demonstrated a relative risk reduction for TE of 54.8% in antico-
agulated patients who had AF at baseline evaluation, supporting
current international guidelines for the use of VKAs in HCM.1,11
The intention to treat analysis was felt to be the most appropri-
ate way of analysing data gathered retrospectively over such a long
period, although we acknowledge that this methodology may have
led to the inclusion of patients who had discontinued VKA therapy
or whose international normalized ratio (INR) was subtherapeutic
at the time of a thrombo-embolic event. Current guidelines rec-
ommend anticoagulation with a CHA2DS2-VASc score of ≥1 in
patients with non-valvular AF, which corresponds to an adjusted
stroke rate of 1.3% per year.10,12,13 The ARR and NNT for patients
in AF at an exploratory threshold of 4% risk of a thrombo-embolic
event over 5 years is 13% (95% CI 2.1–24%) and 7.7, respectively.
Implications for patients in sinus rhythm
The risk of TE in patients who are in SR has not been examined in
detail previously. Risk factors for TE in this group included advanced
age, heart failure symptoms, increased LA diameter, and vascular
disease. While this study does not prove that patients in SR who
have a high estimated risk of TE benefit from anticoagulation prior
to the development of AF, it does support recent recommenda-
tions for frequent ambulatory ECG monitoring in patients with
LA enlargement.1 Irrespective of atrial rhythm, clinicians should
also be alert to conventional vascular risk factors and treat them
appropriately.
Limitations
The patient population in this study is large and diverse, but the
model should only be used in patients with similar characteristics.
It is not validated in paediatric patients (<16 years of age) or in
patients with metabolic or syndromic disorders.
A prospective external validation in a different cohort of patients
would be ideal.
Ethnicity may have influenced the findings. Data on this were not
available in this cohort.
The model includes patients who are treated with a VKA
according to current guidelines. Excluding these patients would
exclude high risk patients and limit the statistical analysis.
Conclusions
The study shows that the risk of TE in patients with HCM can be
identified using a small number of simple clinical features. LA size,
in particular, should be monitored closely, and the assessment and
treatment of conventional vascular risk factors should be routine
practice in older patients. Exploratory analyses show for the first
time evidence for a reduction of TE with VKA treatment. The
CHA2DS2-VASc score does not appear to correlate well with the
clinical outcome in patients with HCM and should not be used to
assess TE risk in this population.
© 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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analysis for centre effect
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